CD19-CAR T-cell therapy induces deep tissue depletion of B cells
2024; BMJ; Volume: 84; Issue: 1 Linguagem: Inglês
10.1136/ard-2024-226142
ISSN1468-2060
AutoresCarlo Tur, Markus Eckstein, Joachim Velden, Simon Rauber, Christina Bergmann, Janina Auth, Laura Bucci, Giulia Corte, Melanie Hagen, Andreas Wirsching, Ricardo Grieshaber‐Bouyer, Petra Reis, Nicolai A. Kittan, Jochen Wacker, Aleix Rius Rigau, Andreas Ramming, Maria Antonietta D’Agostino, Arndt Hartmann, Fabian Müller, Andréas Mackensen, Aline Bözec, Georg Schett, Maria Gabriella Raimondo,
Tópico(s)T-cell and B-cell Immunology
ResumoCD19-targeting chimeric antigen receptor (CAR) T-cell therapy can induce long-term drug-free remission in patients with autoimmune diseases (AIDs). The efficacy of CD19-CAR T-cell therapy is presumably based on deep tissue depletion of B cells; however, such effect has not been proven in humans in vivo.
Referência(s)